Mesoblast Stock Forecast for 2023 - 2025 - 2030
Updated on 04/28/2024
Mesoblast Stock Forecast and Price Target
The average price target for Mesoblast's stock lately set by several renowned analysts is $1.10, which would result in a potential upside of approximately 18.28% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $1.40 and a low estimate of $0.80. If you are interested in MSB stock, it is important to also consider its competitors.
18.28% Upside
Mesoblast Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Price for Mesoblast has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $0.94 – an increase of 100.00%. Over the next eight years, experts anticipate that Fair Value growth for Mesoblast will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDXG Stock Forecast | MiMedx Group | Buy |
6
|
$6.27 | Buy/Sell | $11.85 | 91.39% |
| OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$12.99 | Buy/Sell | $18.00 | 15.47% |
| AXGN Stock Forecast | AxoGen | Buy |
6
|
$6.63 | Buy/Sell | $12.50 | 111.16% |
| LCTX Stock Forecast | Lineage Cell Therapeutics | Outperform |
11
|
$1.14 | Buy/Sell | $5.40 | 338.60% |
| CGEN Stock Forecast | Compugen | Buy |
7
|
$1.92 | Buy/Sell | $4.00 | 160.42% |
Mesoblast Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Mesoblast's Revenue has decreased by 76.68%, from $32.16M to $7.50M. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $18.70M – an increase of 149.33%. Over the next eight years, experts anticipate that Revenue growth for Mesoblast will be 33344.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XTNT Stock Forecast | Xtant Medical Holdings | Buy |
0
|
$0.95 | Buy/Sell | $1.93 | 103.16% |
| PRED Stock Forecast | Predictive Technology Group | - |
0
|
$0.00 | Buy/Sell | $7.00 | 0.00% |
| CRYO Stock Forecast | American CryoStem | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
.jpg)
Mesoblast EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Mesoblast's EBITDA has seen a drop from $-73.49M to $-66.84M – a 9.05% decrease. For next year, the 2 analysts predict EBITDA of $-79.34M, which would mean an increase of 18.70%. Over the next nine years, the pros' prediction is EBITDAof $-100.73M, which would mean a nine-year growth forecast of 50.70%.
Mesoblast EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Mesoblast's EBIT has gone down from $-75.65M to $-69.29M – a 8.41% drop. In the next year, analysts expect EBIT to reach $-83.34M – an increase of 20.28%. According to professional forecasts, in 2030, Mesoblast's EBIT will decrease by 2662.92%, reaching $1.78B.
Mesoblast EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, EPS for Mesoblast has grown by 100.00%, going from $-0.41 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $-0.12 – an increase of 100.00%. Over the next eight years, experts anticipate that EPS growth for Mesoblast will be 100.00%.
.jpg)